Veru Inc.
VERUAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| May 3, 2024 | H.C. Wainwright | Yi Chen | $3.00(+80%) | $1.67 | TheFly |
| Apr 15, 2024 | Oppenheimer | Leland Gershell | $5.00(+229%) | $1.52 | StreetInsider |
| Dec 7, 2022 | H.C. Wainwright | $18.00(+218%) | $5.66 | Benzinga | |
| Apr 15, 2022 | Oppenheimer | Leland Gershell | $36.00(+141%) | $14.95 | Pulse 2.0 |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Canaccord Genuity | maintain | Buy | Jun 4, 2026 |
| Oppenheimer | maintain | Outperform | May 15, 2026 |
| Raymond James | maintain | Outperform | Aug 13, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jan 2, 2025 |
| HC Wainwright & Co. | maintain | Buy | Dec 20, 2024 |
| Oppenheimer | maintain | Outperform | Nov 5, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 13, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 6, 2024 |
| Oppenheimer | maintain | Outperform | Apr 15, 2024 |
| HC Wainwright & Co. | maintain | Buy | Feb 8, 2024 |
| HC Wainwright & Co. | maintain | Buy | Sep 27, 2023 |
| Jefferies | upgrade | Underperform →Hold | Jun 7, 2023 |
| HC Wainwright & Co. | maintain | Buy | May 15, 2023 |
| HC Wainwright & Co. | maintain | Buy | Apr 6, 2023 |
| Oppenheimer | maintain | Outperform | Mar 15, 2023 |
| Oppenheimer | maintain | Outperform | Feb 14, 2023 |
| HC Wainwright & Co. | maintain | Buy | Feb 10, 2023 |
| HC Wainwright & Co. | maintain | Buy | Dec 7, 2022 |
| Cantor Fitzgerald | maintain | Overweight | Dec 5, 2022 |
| HC Wainwright & Co. | maintain | Buy | Nov 10, 2022 |
| Brookline Capital | maintain | Buy | May 18, 2022 |
| Jefferies | maintain | Buy | May 13, 2022 |
| Oppenheimer | maintain | Outperform | Apr 12, 2022 |
| HC Wainwright & Co. | maintain | Buy | Apr 12, 2022 |
| HC Wainwright & Co. | maintain | Buy | Feb 24, 2021 |
Earnings History
Next report: Nov 26, 2026 · EPS est. $-0.25| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 10, 2026 | $-0.30 | $-0.32 | — | $1.7M |
| May 13, 2026 | $-0.13 | $-0.31 | — | $1.9M |
| Feb 11, 2026 | $-0.26 | $-0.47 | — | $2.1M |
| Dec 17, 2025 | $0.05 | $-0.39 | — | $575.0K |
| Aug 12, 2025 | $-0.50 | $-0.55 | — | $650.0K |
| May 8, 2025 | $-0.50 | $-0.60 | — | $725.0K |
| Feb 13, 2025 | $-0.70 | $-0.80 | — | $3.0M |
| Dec 16, 2024 | $-0.60 | $-0.07 | $6.7M | $3.6M |
News
--New positive preclinical studies show that sabizabulin can overcome drug resistance to daraxonrasib with potent anticancer efficacy (IC50=18.2nM) in daraxonrasib resistant human pancreatic cancer cell line which is a drug concentration that can be achieved with current sabizabulin human dosing with good safety-- --Oral sabizabulin had a good safety profile and promising efficacy in previous first-in-man Phase 1b/2 clinical study of 80 subjects with castration resistant and taxane resistant me…
MIAMI, FL, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced that Mitchell Steiner, M.D.
Veru Inc. (VERU) Q3 2026 Earnings Call Transcript
-- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients –